

**Table 1. Characteristics of all included studies**

Study & publicat. Year	Design	Patients (n) Country	Median age (mon.)	Median baseline CD4 count/percentage	Median baseline Viral Load	Treatment	Duration follow-up (months)	Outcome 1 Survival	Outcome 2 Median CD4 count/percentage	Outcome 3 Median Viral Load
Eley <sup>5</sup> 2006	Retrospec Descript	409 (South Africa)	23	11.7% (7%-17.3%) CD4 <15% = 66.2%	5.58 (5.14–6.11)	2 NRTIs + NNRTI or PI (naïve/non-naïve)	12	84% (80-87%)	CD4 < 15% = 10.7%	< 400 copies/ ml = 69.7%
Rouet <sup>6</sup> 2006	Longitud analysis	78 (Cote d'Ivoire)	78	7.5% (2.1%-11.1%)	5.37 (5.07–5.99)	2 NRTIs + NNRTI or PI (naïve)	42	86%	23.1% 36m 24.8% 42m	3.08 36m 2.64 42m
Zhang <sup>7</sup> 2007	Prospectiv Analysis	81 (China)	120 (naïve) 144 (exper)	Naïve: 117 (24-186) Exper: 193 (97-342)	Naïve: 5.53 (5.18-5.71) Exper: 4.85 (3.72-5.33)	AZT + 3TC + NVP	12	–	Naïve: 340 (315-538) Exper: 318 (132-423)	Naïve: 2.60 (<2.6-4.11) Exper: 4.58 (3.88-5.37)
Reddi <sup>8</sup> 2007	Retrospect cohort study	151 (South Africa)	67	7.4% (2.1%-13.7%)	–	2 NRTIs + NNRTI or PI (naïve/non-naïve)	12 (3.5-13.5)	90.9% (84.8-94.6)	At 6 months: + 10.2 (5-13.8) At 12 months: + 16.2% (9.6-20.3)	VL <50c/ml: 84% (6m) 83.3% (12m)
O'Brien <sup>3</sup> 2006	Observat study	1184 (8 CRLS)	84	18-59m: 9.9% (6-13.2) 60-156m: 189.5 (73-339)	–	2 NRTIs + NNRTI (naïve/non-naïve)	12	95%	21.5% (18-59) 517 (60-156)	–
Kline <sup>9</sup> 2007	Study popolation	414 (Romania)	156	292 (1-1143)	5.1 (<2.6-5.9)	Lopinavir/ Ritonavir containing HAART (naïve/non-naïve)	48	–	+ 270 cell (p<0.0001)	< 2.6 (72%)
Song <sup>10</sup> 2007	Observat. Retrospect Study	29 (Kenya)	102	182.3 (± 145.6)	5.11 (± 0.72)	AZT + 3TC + NVP (naïve)	15	100%	363 (± 369)	3.3 (± 0.38)
Puthanakit <sup>11</sup> 2007	Descript Study	107 (Thailand)	91	5.3% (SD 4.9)	5.4 (SD 0.5)	2 NRTIs + NNRTI (naïve)	48	95%	CD4 >25% = 60%	VL <50 = 70% VL 50-1000=4% VL>1000 = 7%
Romanelli <sup>12</sup> 2006	Retrospec. observat. cohort study	43 (Brazil)	29.1 (Triple)	Triple: 20.1%(SD 9.3)	Triple: 5.6 (SD 0.8)	Triple therapy: 2 NRTIs + NNRTI or PI	12	95.5%	+ 4.0% (triple)	- 2.5 (triple)

						(naïve)				
<b>George<sup>13</sup> 2007</b>	Observat. study popolation	236 (Haiti)	75	12% (6%-19%)	5.3 (range:no data)	2 NRTIs + NNRTI ot PI (naive)	24	80%	+ 15% CD4<5% + 11% CD4 5-24% + 5% CD4 > 25%	At 12 months Median VL in undetectable range: 56%
<b>Puthanakit<sup>14</sup> 2007</b>	Prospectiv Observat.	192 (Thailand)	90	171 (± 289) 5.2% (± 4.9%)	5.4 (± 0.5)	2 NRTIs + NNRTI (naive)	12	94.3%	6 months: 431(±425) ; 13.2% ± 6.8 12months: 922(± 492) ; 17.2% (± 7.5)	< 50 cop/ml 67.7%
<b>Wamalwa<sup>15</sup> 2007</b>	Prospectiv Observat	67 (Kenia)	52	288 (101-560) 6.2% (3.6%-10.3%)	18m-3y: 6.4 (6.0-6.6) > 3years: 5.8 (5.3-6.3)	2 NRTIs + NNRTI (naive)	6	91%	536 (273-841) (p<0.001) 15.4% (9.8-21) (p< 0.001)	2.2 (p<0.001)
<b>Bolton-Moore<sup>16</sup> 2007</b>	Open cohort assessment	4875 (Zambia)	81	12.9% (12.5-13.3%) 300 (138-551)	-	2 NRTIs + NNRTI (naive)	24	-	24m: 28.4% (27.4 – 29.4)	-
<b>Machado<sup>17</sup> 2007</b>	Longitud. Observat study	29 (Brazil)	69	486 (7-2690)	4.84 (3.0-5.7)	Previuos treatm without PI 13/29 (44.8%) Previuos treatm with PI 16/29 ( 55.2%) (non-naive)	12	-	65.5% increase CD4 cell count	37.9% complete virol. respons 17.2% partial virol respons 44.8% virol failure
<b>Janssen<sup>18</sup> 2007</b>	Observat. Cohort study	212 (Cambodia)	72	6% (2.6-13) 100 (22-273)	-	d4T+3TC+NVP 68.9% d4T+3TC+EVF 18.8% AZT+3TC+NVP 12.3% (naïve/non-naive)	12	92%	+ 17% (16.3-30.7)	Undetectable 81% 400-1000 3.7% >1000 15.5%
<b>Lodha<sup>19</sup> 2005</b>	Descriptiv Analysis	26 (North India)	69	584 (± 685.9)	-	D4T+3TC+NVP 57.6% AZT+3TC+NVP 29.6% d4T+ddl+NVP 7.6% (naïve)	6	96.2%	699.8 (± 500.6)	-

<b>Nyandiko<sup>20</sup> 2006</b>	Retrospect review	279 (Kenya)	72	Orphans: 9% (1-33) 259 (4-942) Non-orphans: 10% (1-41) 169 (4-1744)	–	AZT+3TC+NVP child < 10kg d4T+3TC+NVP child > 10kg (naïve)	33 (orphaned) 41 (non-orph)	95%	–	–
<b>Puthanakit<sup>21</sup> 2005</b>	Prospectiv Study	107 (Thailand)	NPV: 85.2 EFV: 102	<b>NVP</b> 4% (1-9%) ≤ 6 years: 61 (38-314) > 6 years: 46 (30-103) <b>EFV:</b> 3% (1-10%) ≤ 6 years: 228 (42-538) > 6 years: 47 (21-128)	NVP: 5.3 (± 0.5) EFV: 5.4 (± 0.4)	3TC+d4T+NVP Or 3TC+d4T+EFV (naïve)	18	96.3%	21% (15-26%) 532 (287-709)	NVP: 3.1 (± 1.0) EFV: 3.6 (± 0.5)